0.90% -0.0039

시간 외 거래: .45 0.019 +4.41%

Calidi Biotherapeutics Inc (CLDI)

개요 뉴스 가격 이력 토론 예측

Calidi Biotherapeutics Inc 주식(CLDI)의 최신 뉴스

Calidi Biotherapeutics Inc (CLDI)

Calidi Biotherapeutics Inc 주식(CLDI)의 최신 뉴스

Candel Therapeutics (NASDAQ:CADL) vs. Calidi Biotherapeutics (NYSE:CLDI) Critical Review - Defense World

Geode Capital Management LLC Buys 120,406 Shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5 - The Globe and Mail

Calidi Biotherapeutics (NYSE:CLDI) Stock Price Down 0.3% – Time to Sell? - Defense World

Investor’s Delight: Calidi Biotherapeutics Inc (CLDI) Closes Weak at 0.65, Down -6.53 - DWinneX

Calidi (CLDI) Advances Cancer Treatment with IL15 Superagonist a - GuruFocus

Calidi Biotherapeutics Announces IL15 Superagonist as First - GlobeNewswire

Revolutionary Cancer Treatment Platform Shows Complete Tumor Elimination: First Systemic Delivery Success - Stock Titan

Calidi Biotherapeutics (CLDI) Awards Stock Option to New CEO Eri - GuruFocus

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - The Manila Times

Calidi Bio's Strategic Move: New CEO Secures 726K Share Options with 4-Year Performance Lock - Stock Titan

Calidi Biotherapeutics appoints new CEO By Investing.com - Investing.com South Africa

Zealand names former Lilly exec Singh as CSO - BioCentury

Calidi Biotherapeutics appoints new CEO - Investing.com

Calidi (CLDI) Appoints New CEO as Eric Poma Assumes Leadership | - GuruFocus

Calidi Biotherapeutics Appoints New CEO Eric Poma - TipRanks

Calidi Biotherapeutics Announces Chief Executive Officer Transition And Appointment Of Eric Poma, Ph.D. As CEO And Director - TradingView

Calidi Biotherapeutics Announces Chief Executive Officer - GlobeNewswire

New Calidi Bio CEO Brings $400M Funding Success Record: Strategic Shift for Cancer Treatment Pioneer - Stock Titan

Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor - The Globe and Mail

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24 - The Manila Times

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24 - GlobeNewswire

Cancer Breakthrough Alert: Top Oncologist Reveals New FDA-Cleared Stem Cell Therapy Development - Stock Titan

Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors - The Manila Times

FDA Green Lights Revolutionary Cancer Treatment: Stem Cells Combined With Virus to Fight Multiple Tumors - Stock Titan

Calidi Biotherapeutics Announces Appointment of Guy Travis - GlobeNewswire

Cancer Drug Developer Calidi Bio Strengthens Leadership: Renowned Oncologist Takes CMO Role - Stock Titan

Calidi Biotherapeutics Appoints New Chief Medical Officer - TipRanks

CLDI stock touches 52-week low at $0.42 amid market challenges By Investing.com - Investing.com South Africa

CLDI stock touches 52-week low at $0.42 amid market challenges - Investing.com India

Press Release Distribution & PR Platform - ACCESS Newswire

ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire

HighTower Advisors LLC Makes New Investment in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World

Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire

CLDI stock plunges to 52-week low, hitting $0.57 amid market challenges By Investing.com - Investing.com South Africa

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights - The Manila Times

Calidi Bio Raises Fresh $3.9M Capital to Advance Clinical Programs - Stock Titan

Calidi Biotherapeutics Cuts Losses by 50% While Expanding Cancer Gene Therapy Trials - Stock Titan

CLDI stock plunges to 52-week low, hitting $0.57 amid market challenges - Investing.com India

Virtu Financial LLC Buys Shares of 73,448 Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World

Calidi Biotherapeutics sinks after pricing $3.9M registered direct offering - MSN

Calidi prices 3.33M shares at 65c in registered direct offering - TipRanks

Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire

Calidi Bio Secures Strategic $3.9M Investment to Accelerate Cancer Immunotherapy Pipeline - Stock Titan

Calidi Biotherapeutics Provides Update On Phase 1 Trial Of CLD-101 For Recurrent Glioma - Nasdaq

Calidi Biotherapeutics and City of Hope Provide Update on a - GlobeNewswire

Calidi Biotherapeutics And City Of Hope Provide Update On A Phase 1 Clinical Trial With CLD-101 Virotherapy In Patients With Recurrent High-Grade Glioma - MarketScreener

Breakthrough Brain Cancer Treatment Advances: 14 Patients Successfully Treated in Groundbreaking Trial - Stock Titan

CLDI stock touches 52-week low at $0.73 amid market challenges - MSN

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Weatherford Democrat

IBN Coverage: Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform - Yahoo Finance

CLDI과 유사한 종목